David R. Ha, PharmD, BCIDP

Obesity significantly impacts the pharmacokinetics (PK) of antifungal drugs like echinocandins, including volume of distribution (Vd) and clearance. However, despite these PK differences, current clinical evidence generally does not support the need for universal dose adjustments in obese patients. Clinicians should consider personalized dosing based on patient characteristics, infection severity, and specific drug properties due to echinocandins' favorable safety profiles.

There is value in leveraging the contributions of nurses, laboratorians, and informaticists in antimicrobial stewardship.

There is limited and conflicting data regarding the role of combination antifungal therapy for treatment of invasive mucormycosis.

Staff nurses are underused but potentially valuable contributors to antibiotic stewardship.